Plant Name: tripolium vulgare
Taxonomic Information:
Plant ID: NPO32468
Plant Latin Name: tripolium vulgare
Taxonomy Genus: Tripolium
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
587543
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PTPN1; | |
| CA2; CA7; CA4; CA12; | |
| AKR1B10; AKR1B1; | |
| APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.645E-11 | 3.582E-07 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.073E-10 | 7.701E-06 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.628E-09 | 1.182E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.502E-07 | 1.400E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0044597; daunorubicin metabolic process | 4.198E-06 | 7.031E-03 | AKR1B1, AKR1B10 |
| BP | GO:0008152; metabolic process | GO:0044598; doxorubicin metabolic process | 4.198E-06 | 7.031E-03 | AKR1B1, AKR1B10 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 6.743E-06 | 9.177E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.573E-06 | 9.177E-03 | CA12, CA2, CA4, CA7, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0004033; aldo-keto reductase (NADP) activity | 4.854E-05 | 4.228E-02 | AKR1B1, AKR1B10 |
| CC | GO:0044464; cell part | GO:0005791; rough endoplasmic reticulum | 1.677E-04 | 1.074E-01 | APP, CA4 |
| CC | GO:0043226; organelle | GO:0031982; vesicle | 1.048E-03 | 2.908E-01 | AKR1B1, AKR1B10, APP, CA2, CA4, PTPN1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.495E-11 | 3.991E-10 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 3.527E-05 | 2.761E-04 | CA2, CA4 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 8.761E-05 | 2.803E-04 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 6.056E-05 | 2.761E-04 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00561 | Glycerolipid metabolism | 2.368E-04 | 6.316E-04 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 6.903E-05 | 2.761E-04 | AKR1B10, AKR1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04966 | Collecting duct acid secretion | 1.075E-02 | 2.457E-02 | CA2 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04971 | Gastric acid secretion | 2.922E-02 | 4.676E-02 | CA2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.922E-02 | 4.676E-02 | PTPN1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.805E-02 | 4.676E-02 | CA2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| NA: NA | Geographic retinal atrophy | NA | APP; |
| C00-D49: Neoplasms | Glioma | C71 | APP; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
